Raphael J. Landovitz, MD

Raphael J. Landovitz, MD

Infectious Diseases
Primary Location
CARE Center
1399 Roxbury Drive
Suite 100
Los Angeles, California 90035
Phone
Fax
310-557-3450

About

Dr. Landovitz joined the UCLA CARE Center in 2006 after training at Harvard Medical School, Brigham and Women's Hospital, and Massachusetts General Hospital. He also served as medical co-director for the Vietnam CDC Harvard Medical School AIDS Partnership in Ho Chi Minh City, Vietnam. He is an infectious disease and HIV clinician with both a clinical and research interest in HIV and STI prevention, particularly the use of chemoprophylaxis as part of HIV and STI prevention - PrEP, PEP, and microbicides.  He works in the NIH/Division of AIDS-funded ACTG, HPTN and ATN clinical trials networks. He was awarded the John Carey Young Investigator Award by the ACTG in June 2010, and the HIVMAA HIV research award in 2017. He led the NIH-funded clinical trials that supported the 2021 FDA approval of long-acting injectable cabotegravir for HIV PrEP.  Dr. Landovitz lectures and teaches internationally on HIV Prevention, including pre-and post-exposure prophylaxis.

Languages

English

Education

Medical Board Certification

Infectious Disease, American Board of Internal Medicine, 2001

Fellowship

Harvard Medical School/Massachusetts General Hospital, 2001

Residency

Brigham and Women's Hospital, 1999

Internship

Brigham and Women's Hospital, 1997

Degree

Harvard Medical School, MD, 1996

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Areas of Focus

Pre exposure prophylaxis (prep)
Hiv testing
Antiretroviral salvage therapy
Sexually transmitted disease (std)
Human immunodeficiency virus (hiv)
Acquired immunodeficiency syndrome (aids)

Research

Interests

  • HIV Prevention (including PEP, PrEP and other combination prevention strategies)
  • HIV and STD diagnosis and treatment

Awards

  • Top Doctors, Los Angeles Magazine, 2022
  • Super Doctors, 2022